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Chronic kidney disease, as defined by albuminuria or
decreased estimated glomerular filtration rate (eGFR),
affects 11.6% of the adult population in the United States.
CKD frequently occurs in association with diabetes and
hypertension, suggesting that vascular disease is a likely
cause in many people. We provide data on the frequency
of diabetes, hypertension, or both, according to albumin-to-
creatinine ratio and eGFR, and review the rationale for
retaining the current name.
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Chronic kidney disease is one of a number of chronic diseases
affecting primarily the elderly and leading to an increased
risk of cardiovascular disease (CVD). Similar to diabetes and
hypertension, it is silent in its early stages, but can be detected
by simple laboratory measurements. Once detected, CKD can
be treated, thereby reducing the risk of adverse outcomes.
Thus, CKD is now the target of public health programs for
early detection and treatment. The prevalence of CKD in
the United States has recently been estimated as 11.6% of
the adult population (23 million),1 compared with 10.6%
(23.4 million) for diabetes, 33.3% (73.6 million) for hyper-
tension, and 36.3% (80.0 million) for CVD.2
Chronic kidney disease prevalence estimates are based on
laboratory measures of kidney disease in epidemiological
surveys, principally albuminuria as a marker of kidney
damage, and GFR estimated from serum creatinine. Critics of
the definition of CKD claim that the estimates of CKD
prevalence are too high compared with the prevalence of
kidney failure treated by dialysis and transplantation, the
end-stage of CKD (prevalence ratio of 50 cases of CKD for
every 1 case of treated kidney failure), raising questions about
the appropriateness of the methods for assessing kidney
damage and GFR, and the cutoff values used to define the
disease. In this issue of Kidney International, Professor
Meguid El Nahas reviews these critiques, defends the
rationale for using these laboratory measures of kidney
disease, describes a unifying hypothesis, and proposes a new
term ‘cardio-kidney-damage’ to emphasize the link between
heart and kidney disease.3 We agree with the importance of
vascular disease in kidney disease and, like Professor El
Nahas, have struggled with finding the best name for these
laboratory abnormalities in the presence of multiple chronic
diseases in an aging population. However, we do not think
that the proposed name ‘cardio-kidney-damage’ will be
helpful. Furthermore, we think ‘cardio-kidney-damage,’
having the same acronym (CKD) will lead to confusion
rather than clarity.
Professor El Nahas hypothesizes that ‘individuals who are
genetically predisposed and exposed throughout their life
course to CVD risk factors including hypertension and
diabetes develop age-related vascular pathology including
diffuse atherosclerosis affecting the kidneys. Therefore CKD
as currently defined and detected in a large percentage of the
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general population is merely a manifestation of age-related
systemic vascular pathology and not a primary renal disease
as such.’ He goes on to conclude that ‘Albuminuria and
reduction in GFR are simply markers of the severity of the
vascular disease. Describing these individuals as having CKD
places an inappropriately selective emphasis on the kidney.
Describing them as suffering from Cardio-Kidney-Damage
may reflect a more accurate and broader perception of this
major healthcare issue.’
We would certainly agree with Professor El Nahas that
decreased GFR and albuminuria are kidney measures—that
is, they reflect kidney function and structure. There can be
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Figure 1 |Prevalence of diabetes and hypertension in the United States according to estimated glomerular filtration rate (eGFR)
and albuminuria (National Health and Nutrition Examination Survey 1988–2006). Data are based on 44,769 people from a multistage
probability random sample designed to be representative of the noninstitutionalized adult US population. Albumin-to-creatinine ratio is
based on a single measurement. Diabetes is defined as self-reported physician diagnosis. Hypertension is defined as systolic blood pressure
X140mmHg, diastolic blood pressure X90mmHg, or self-reported hypertension medication use. The accompanying tables give the
number of people and percentage of the US population in each eGFR category. Within each GFR category, the number and percentage,
and age distribution are given for each albuminuria category. Alb, albumin; Cr, creatinine.
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no serious disagreement with this statement. As nephro-
logists, these are the ‘tools of our trade.’ Recent studies
show that reduced eGFR and higher levels of albuminuria are
independent risk factors for adverse outcomes.4,5 We also
agree with the recognition of vascular disease as the likely
cause of decreased GFR and albuminuria in aging,6 with
diabetes, hypertension, or both found in a large fraction of
those with CKD. As shown in Figure 1, an albumin-to-
creatinine ratio 430mg/g is associated with diabetes,
hypertension, or both in 490% of individuals with eGFR
o60 (median age over 70 years), in about 70% of people
with eGFR 60–89ml/min per 1.73m2 (median age about 60
years), and in more than 30% of people with eGFR490ml/
min per 1.73m2 (median age under 25 years).
However, we do not agree that the distinction of whether a
condition is ‘primary’ or ‘secondary’ should be the basis for
distinguishing ‘disease’ from ‘damage.’ First, often we are
uncertain of the cause of kidney diseases. Second, knowledge
of the cause of kidney disease is not sufficient to understand
or treat its consequences. Third, most cases of kidney failure,
unarguably a disease, are considered secondary to diabetes
and/or hypertension with no clear ‘primary’ kidney disease.
Furthermore, we do not agree that emphasis on the kidney
is inappropriate. Indeed, the laboratory abnormalities are
kidney measures. Having CKD does not exclude having
CVD or CVD risk factors. It would be confusing to use
albuminuria or decreased GFR to make statements about the
entire vasculature.
We would probably all agree that the ultimate value of the
name ‘CKD’ should be judged based on its ability now and
in the future to guide medical care and improve patient
outcomes. Table 1 summarizes the suggested therapies for
CKD. Although it is unfortunate that there is no treatment as
of yet to raise the GFR, analogous to lowering blood glucose
in patients with diabetes or lowering blood pressure in
patients with hypertension, there are treatments to reduce
proteinuria, and patients with CKD require different care
than those with CVD or CVD risk factors but without CKD.
In particular, recommended blood pressure targets for
preventing kidney disease progression and CVD are lower
in patients with kidney disease compared with those without
kidney disease (although not in patients with diabetes),
and blood pressure agents for patients with albuminuria
(angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers) differ for those without albuminuria
(thiazide diuretics). Patients with CKD are more likely to
experience toxicity from the side effects of iodine-based and
gadolinium-based contrast agents for vascular imaging.
These and other threats to patient safety must be considered
in caring for patients with CKD.7 More research is needed to
understand the relationship of CKD to adverse outcomes and
to develop more effective therapies.
The decision to use the term ‘disease’ rather than ‘damage’
was carefully considered by the Kidney Disease Outcome
Quality Initiative Workgroup, which developed the clinical
practice guideline in 2002,8 and at the Kidney Disease
Improving Global Outcomes (KDIGO) Conference in 2004,9
which endorsed the name and definition. The Oxford English
Dictionary (Compact Edition) defines a disease as ‘A disorder
of structure or function in a human, animal, or plant, especially
one that produces specific symptoms.’10 The following justifica-
tion is taken from the KDIGO 2005 report.9 ‘Evidence in
support of a disease include clinical-pathological correlations
(as defined by case series), associations with symptoms or
findings (as defined by cross-sectional analyses), and associa-
tions with outcomes (as defined by longitudinal analyses). The
use of the term ‘disease’ in CKD is consistent with: (1) the need
for action to improve outcomes through prevention, detection,
evaluation and treatment; (2) providing a message for public,
physician and patient education programs; (3) common usage;
and (4) its use in other conditions defined by findings and
laboratory tests, such as hypertension, diabetes, and hyper-
lipidemia.’ Recent critiques of the use of the term ‘disease’ have
asked whether the ‘disadvantage’ associated with CKD justifies
this term.11 A recent KDIGO Controversies Conference on
prognosis in CKD specifically evaluated the risks associated
with decreased GFR and albuminuria.12 A report on this
conference will be published in a forthcoming issue of
Kidney International.
In conclusion, the discomfort among nephrologists about
the high prevalence of CKD compared with treated kidney
failure is understandable. This is a time of transition, from
Table 1 | Suggested therapies in clinical practice guidelines for chronic kidney diseasea
Raise GFR None so far
Reducing albuminuria Lower blood pressure goal, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers
Slowing kidney disease
progression
Lower blood pressure goal, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers, if proteinuria
Preventing and treating
complications
Erythropoiesis-stimulating agents, supplemental iron, phosphate binders, vitamin D analogs, calcimimetics
Reducing CVD risk Achieving blood pressure goals, more frequent monitoring of kidney function and serum electrolytes, avoidance of
statins and fibrates in combination, choice of agents for type 2 diabetes
Reducing infection risk Immunizations for influenza, pneumonia, and hepatitis B
Improving patient safety Appropriate dose reduction for drugs cleared by the kidney; avoiding unnecessary use of nephrotoxic agents
(nonsteroidal anti-inflammatory drugs, intravenous contrast, phosphate bowel preparations)
Abbreviations: CVD, cardiovascular disease; GFR, glomerular filtration rate.
aEvidence from randomized clinical trials with ‘hard’ clinical end points is available for only a few therapies.
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viewing kidney disease as a life-threatening condition
affecting only a few people who require lifelong care by
nephrologists, to a common condition that is the target for
prevention, early detection, and management by non-
nephrologist physicians, and public health systems. Although
the name ‘CKD’ does not shed light on specific causes of
disease, it has provided a useful and coherent framework for
identification of a high-risk population in need of both
immediate action and acquisition of new knowledge.
Whether and how the name can be improved is debatable,
but we hope that such debates will not detract from the
more important goal of bringing together nephrologists
and non-nephrologists to focus on improving patient
outcomes.
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